Cardiovascular Safety in Drug Development: State-of-the-Art Assessments

Posted:
25
March 2011

Join Richmond Pharmacology at this year�s Cardiovascular Safety in Drug Development: State-of-the-Art Assessments, taking place in Washington, USA from April 14 to 15.Featured topics will include QT issues in drug development, New approaches to QT analysis, Phase 3 development when there is a QT signal, Post-marketing surveillance, Ischemic events, Bleeding, Blood pressure and In what situations outcomes studies are necessary.Richmond Pharmacology�s CEO, Dr Jorg Taubel will be presenting the abstract; Can Food Serve as a Non-pharmacological Control in Thorough Cardiac Safety Studies, on Day 1, Session 3. This presentation will provide an insight into the effect of food on heart rate under the conditions of a Thorough QT (TQT) study. Dr Taubel has worked in clinical pharmacology for over 20 years and has been involved in the conduct of more than 400 early phase studies.For a detailed schedule of the meeting please click hereChaired by Dr Philip T. Sager, the meeting will feature presentations and commentary from leading industry, academic and regulatory speakers with advice on how to optimize cardiovascular safety assessment. For information on how to register for the conference click hereIf you would like to meet with Dr Taubel to discuss your QT requirements and how Richmond Pharmacology can help develop your program please email us at info@richmondpharmacology.com and we will try our best to accommodate your request. Be assured that your study will be managed by experts with unparalleled clinical excellence.We hope to see you in Washington to learn more about Richmond Pharmacology and what you can expect from Europe�s leading Early Phase Full-Service CRO.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more